Van ECK Associates Corp Sells 119,773 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Van ECK Associates Corp lowered its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 23.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 385,484 shares of the company's stock after selling 119,773 shares during the quarter. Van ECK Associates Corp owned about 0.11% of Bausch Health Companies worth $3,092,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Bfsg LLC bought a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $63,000. Ausdal Financial Partners Inc. purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $86,000. Jump Financial LLC bought a new position in Bausch Health Companies in the third quarter worth approximately $92,000. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in Bausch Health Companies during the third quarter worth $103,000. Finally, Park Avenue Securities LLC bought a new stake in Bausch Health Companies during the 3rd quarter valued at $169,000. Institutional investors own 78.65% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BHC shares. StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Wednesday, February 7th. Royal Bank of Canada reduced their price target on Bausch Health Companies from $12.00 to $11.00 and set a "sector perform" rating on the stock in a research report on Tuesday, April 23rd. Piper Sandler raised their price objective on Bausch Health Companies from $7.00 to $9.00 and gave the stock a "neutral" rating in a research report on Monday, April 29th. Finally, Jefferies Financial Group cut their price objective on shares of Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Bausch Health Companies currently has an average rating of "Hold" and an average price target of $11.33.

Bausch Health Companies Stock Performance

NYSE BHC traded down $0.10 on Tuesday, hitting $7.42. 2,282,690 shares of the company's stock traded hands, compared to its average volume of 2,838,404. The firm's 50-day moving average price is $9.23 and its two-hundred day moving average price is $8.22. Bausch Health Companies Inc. has a 1-year low of $5.57 and a 1-year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.14. The company had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 2,370.91%. The firm's quarterly revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.02 earnings per share. As a group, analysts predict that Bausch Health Companies Inc. will post 3.96 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.